Viracta Therapeutics Inc.

0.02
-0.00 (-16.67%)
At close: Mar 18, 2025, 3:59 PM
0.02
0.00%
After-hours: Mar 18, 2025, 03:59 PM EDT
-16.67%
Bid 0.02
Market Cap 973.73K
Revenue (ttm) 741.17K
Net Income (ttm) -43.48M
EPS (ttm) -1.1
PE Ratio (ttm) -0.02
Forward PE -0.4
Analyst Buy
Ask 0.02
Volume 35,002
Avg. Volume (20D) 1,460,032
Open 0.02
Previous Close 0.02
Day's Range 0.02 - 0.02
52-Week Range 0.01 - 1.31
Beta 0.31

About VIRX

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as we...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 27, 2005
Employees 26
Stock Exchange NASDAQ
Ticker Symbol VIRX
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for VIRX stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 12144.90% from the latest price.

Stock Forecasts
7 months ago
-11.76%
Viracta Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
11 months ago
-32.17%
Viracta Therapeutics shares are trading lower. The company announced topline results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial from both arms of the relapsed or refractory Epstein-Barr virus-positive peripheral T-cell lymphoma cohort.